pharmaphorum
SEPTEMBER 30, 2022
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No.
PM360
SEPTEMBER 21, 2023
They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
SEPTEMBER 21, 2023
Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re
Clarivate
MAY 14, 2024
Competition is expected to intensify in the next few years as both Novo Nordisk and Eli Lilly plan to launch their respective weight-loss drugs in Mainland China. Robust clinical data around multiple cardiometabolic indicators supported by all three assets is poised to lead widespread adoption in Mainland China.
pharmaphorum
JANUARY 10, 2023
billion by 2026, according to research by the Business Research Company. If you have to wait to extract meaning from your data then you won’t be competitive enough. “A This dynamic approach can also be used to predict and recommend next-best actions in sales and marketing, while both improving the customer experience and ROI.
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Given the volume of 340B sales (13% of total U.S. Quality and value measurements commonly used outside of the U.S. The 340B battle will rage on.
pharmaphorum
OCTOBER 17, 2022
It remains to be seen whether the data from VALOR will convince the regulator to grant conditional approval while it waits for results from a confirmatory phase 3 trial (ATLAS ) in SOD1-ALS, which is due to generate results in 2026.
Expert insights. Personalized for you.
57 
Let's personalize your content